Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 3/2017

Open Access 01-04-2017 | Review

Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover

Authors: Thorbjørn Krejsgaard, Lise M. Lindahl, Nigel P. Mongan, Mariusz A. Wasik, Ivan V. Litvinov, Lars Iversen, Erik Langhoff, Anders Woetmann, Niels Odum

Published in: Seminars in Immunopathology | Issue 3/2017

Login to get access

Abstract

Cutaneous T-cell lymphomas (CTCL) are characterized by the presence of chronically inflamed skin lesions containing malignant T cells. Early disease presents as limited skin patches or plaques and exhibits an indolent behavior. For many patients, the disease never progresses beyond this stage, but in approximately one third of patients, the disease becomes progressive, and the skin lesions start to expand and evolve. Eventually, overt tumors develop and the malignant T cells may disseminate to the blood, lymph nodes, bone marrow, and visceral organs, often with a fatal outcome. The transition from early indolent to progressive and advanced disease is accompanied by a significant shift in the nature of the tumor-associated inflammation. This shift does not appear to be an epiphenomenon but rather a critical step in disease progression. Emerging evidence supports that the malignant T cells take control of the inflammatory environment, suppressing cellular immunity and anti-tumor responses while promoting a chronic inflammatory milieu that fuels their own expansion. Here, we review the inflammatory changes associated with disease progression in CTCL and point to their wider relevance in other cancer contexts. We further define the term “malignant inflammation” as a pro-tumorigenic inflammatory environment orchestrated by the tumor cells and discuss some of the mechanisms driving the development of malignant inflammation in CTCL.
Literature
1.
Willemze R, Jaffe ES, Burg G et al (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785PubMedCrossRef
2.
Scarisbrick JJ, Kim YH, Whittaker SJ et al (2014) Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? Br J Dermatol 170:1226–1236PubMedCrossRef
3.
Wilcox RA (2016) Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 91:151–165PubMedCrossRef
4.
Agar NS, Wedgeworth E, Crichton S et al (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28:4730–4739PubMedCrossRef
5.
Scarisbrick JJ, Prince HM, Vermeer MH et al (2015) Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 33:3766–3773PubMedPubMedCentralCrossRef
6.
Diwan AH, Prieto VG, Herling M et al (2005) Primary Sezary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism. Am J Clin Pathol 123:510–515PubMedCrossRef
7.
Ferenczi K, Fuhlbrigge RC, Pinkus J et al (2002) Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 119:1405–1410PubMedCrossRef
8.
Kallinich T, Muche JM, Qin S et al (2003) Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol 121:1045–1052PubMedCrossRef
9.
Campbell JJ, Clark RA, Watanabe R et al (2010) Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116:767–771PubMedPubMedCentralCrossRef
10.
Sugaya M, Morimura S, Suga H et al (2015) CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol 42:613–615PubMedCrossRef
11.
Fujita Y, Abe R, Sasaki M et al (2006) Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides. Clin Cancer Res 12:2670–2675PubMedCrossRef
12.
Lu D, Duvic M, Medeiros LJ et al (2001) The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol 115:413–421PubMedCrossRef
13.
Tensen CP, Vermeer MH, van der Stoop PM et al (1998) Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas. J Invest Dermatol 111:222–226PubMedCrossRef
14.
Miyagaki T, Sugaya M (2014) Immunological milieu in mycosis fungoides and Sezary syndrome. J Dermatol 41:11–18PubMedCrossRef
15.
Krejsgaard T, Odum N, Geisler C et al (2012) Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome. Leukemia 26:424–432PubMedCrossRef
16.
Litvinov IV, Tetzlaff MT, Rahme E et al (2015) Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med 4:1440–1447PubMedPubMedCentralCrossRef
17.
Litvinov IV, Tetzlaff MT, Rahme E et al (2015) Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer 121:1993–2003PubMedPubMedCentralCrossRef
18.
Willerslev-Olsen A, Krejsgaard T, Lindahl LM et al (2013) Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel) 5:1402–1421CrossRef
19.
20.
Ungewickell A, Bhaduri A, Rios E et al (2015) Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet 47:1056–1060PubMedCrossRef
21.
Kiel MJ, Sahasrabuddhe AA, Rolland DC et al (2015) Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome. Nat Commun 6
22.
Wang L, Ni X, Covington KR et al (2015) Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47:1426–1434PubMedPubMedCentralCrossRef
23.
da Silva Almeida AC, Abate F, Khiabanian H et al (2015) The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome. Nat Genet 47:1465–1470PubMedPubMedCentralCrossRef
24.
Woollard WJ, Pullabhatla V, Lorenc A et al (2016) Candidate driver genes in Sezary syndrome: frequent perturbations of genes involved in genome maintenance and DNA repair. Blood 127:3387–3397PubMedCrossRef
25.
26.
Belloni B, Johansen N, Glass LF et al (2012) Recent advances in the management of cutaneous lymphomas. Semin Oncol 39:150–162PubMedCrossRef
27.
28.
Wood GS, Edinger A, Hoppe RT et al (1994) Mycosis fungoides skin lesions contain CD8+ tumor-infiltrating lymphocytes expressing an activated, MHC-restricted cytotoxic T-lymphocyte phenotype. J Cutan Pathol 21:151–156PubMedCrossRef
29.
Asadullah K, Friedrich M, Docke WD et al (1997) Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early primary cutaneous T-cell lymphoma. J Invest Dermatol 108:743–747PubMedCrossRef
30.
Bagot M, Echchakir H, Mami-Chouaib F et al (1998) Isolation of tumor-specific cytotoxic CD4+ and CD4 + CD8dim + T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 91:4331–4341PubMed
31.
Echchakir H, Bagot M, Dorothee G et al (2000) Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 115:74–80PubMedCrossRef
32.
Vermeer MH, van Doom R, Dukers D et al (2001) CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 19:4322–4329PubMedCrossRef
33.
Hsi AC, Lee SJ, Rosman IS et al (2015) Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implications. J Am Acad Dermatol 72:159–167PubMedCrossRef
34.
Hoppe RT, Medeiros LJ, Warnke RA et al (1995) CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 32:448–453PubMedCrossRef
35.
Berger CL, Wang N, Christensen I et al (1996) The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 107:392–397PubMedCrossRef
36.
Bouaziz JD, Ortonne N, Giustiniani J et al (2005) Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in Sezary syndrome patients. J Invest Dermatol 125:1273–1278PubMedCrossRef
37.
Abeni D, Frontani M, Sampogna F et al (2005) Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol 153:324–330PubMedCrossRef
38.
Vowels BR, Lessin SR, Cassin M et al (1994) Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 103:669–673PubMedCrossRef
39.
Papadavid E, Economidou J, Psarra A et al (2003) The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 148:709–718PubMedCrossRef
40.
Hahtola S, Tuomela S, Elo L et al (2006) Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res 12:4812–4821PubMedCrossRef
41.
Geskin LJ, Viragova S, Stolz DB et al (2015) Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood 125:2798–2805PubMedPubMedCentralCrossRef
42.
Johnson VE, Vonderheid EC, Hess AD et al (2014) Genetic markers associated with progression in early mycosis fungoides. J Eur Acad Dermatol Venereol 28:1431–1435PubMedCrossRef
43.
Netchiporouk E, Litvinov IV, Moreau L et al (2014) Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle 13:3331–3335PubMedPubMedCentralCrossRef
44.
Axelrod PI, Lorber B, Vonderheid EC (1992) Infections complicating mycosis fungoides and Sezary syndrome. JAMA 267:1354–1358PubMedCrossRef
45.
Miyagaki T, Sugaya M, Suga H et al (2012) Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma. J Invest Dermatol 132:1280–1289CrossRef
46.
Bromley SK, Mempel TR, Luster AD (2008) Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 9:970–980PubMedCrossRef
47.
Kakinuma T, Sugaya M, Nakamura K et al (2003) Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 48:23–30PubMedCrossRef
48.
Miyagaki T, Sugaya M, Suga H et al (2013) Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis. J Eur Acad Dermatol Venereol 27:e60–e67PubMedCrossRef
49.
Tuzova M, Richmond J, Wolpowitz D et al (2015) CCR4+ T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16. Leuk Lymphoma 56:440–449PubMedCrossRef
50.
Miyagaki T, Sugaya M, Fujita H et al (2010) Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 130:2304–2311CrossRef
51.
Gunther C, Zimmermann N, Berndt N et al (2011) Up-regulation of the chemokine CCL18 by macrophages is a potential immunomodulatory pathway in cutaneous T-cell lymphoma. Am J Pathol 179:1434–1442PubMedPubMedCentralCrossRef
52.
Sallusto F, Mackay CR, Lanzavecchia A (1997) Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277:2005–2007PubMedCrossRef
53.
54.
Duvic M, Pinter-Brown LC, Foss FM et al (2015) Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 125:1883–1889PubMedPubMedCentralCrossRef
55.
Miyagaki T, Sugaya M, Suga H et al (2011) IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 17:7529–7538PubMedCrossRef
56.
Ito M, Teshima K, Ikeda S et al (2014) Micro RNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma. Blood 123:1499–1511PubMedCrossRef
57.
Ikeda S, Kitadate A, Ito M et al (2016) Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma. Oncotarget 7:13563–13574PubMedPubMedCentral
58.
Asadullah K, Docke WD, Haeussler A et al (1996) Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 107:833–837PubMedCrossRef
59.
Asadullah K, Haeussler-Quade A, Gellrich S et al (2000) IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Exp Dermatol 9:248–251PubMedCrossRef
60.
Mishra A, La PK, Kwiatkowski S et al (2016) Mechanism, consequences and therapeutic targeting of abnormal IL-15 signaling in cutaneous T-cell lymphoma. Cancer Discov 6:986–1005PubMedCrossRef
61.
Blaschke V, Reich K, Middel P et al (1999) Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. J Invest Dermatol 113:658–663CrossRef
62.
63.
van Kester MS, Borg MK, Zoutman WH et al (2012) A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol 132:2050–2059CrossRef
64.
Ohmatsu H, Humme D, Gulati N et al (2014) IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization. Cancer Immunol Res 2:890–900PubMedPubMedCentralCrossRef
65.
Suga H, Sugaya M, Miyagaki T et al (2014) The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol 134:1428–1435PubMedCrossRef
66.
Rook AH, Kubin M, Cassin M et al (1995) IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 154:1491–1498PubMed
67.
Wilcox RA, Wada DA, Ziesmer SC et al (2009) Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114:2936–2944PubMedPubMedCentralCrossRef
68.
Krejsgaard T, Gjerdrum LM, Ralfkiaer E et al (2008) Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome. Leukemia 22:2230–2239PubMedCrossRef
69.
Richmond J, Tuzova M, Parks A et al (2011) Interleukin-16 as a marker of Sezary syndrome onset and stage. J Clin Immunol 31:39–50PubMedCrossRef
70.
Ciree A, Michel L, Camilleri-Broet S et al (2004) Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome. Int J Cancer 112:113–120PubMedCrossRef
71.
Krejsgaard T, Ralfkiaer U, Clasen-Linde E et al (2011) Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat 3 signaling pathway. J Invest Dermatol 131:1331–1338PubMedCrossRef
72.
Fontao L, Brembilla NC, Masouye I et al (2012) Interleukin-17 expression in neutrophils and Th17 cells in cutaneous T-cell lymphoma associated with neutrophilic infiltrate of the skin. Br J Dermatol 166:687–689PubMedCrossRef
73.
Wolk K, Mitsui H, Witte K et al (2014) Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function. Clin Cancer Res 20:5507–5516PubMedCrossRef
74.
Franck N, Carlotti A, Gorin I et al (2005) Mycosis fungoides-type cutaneous T-cell lymphoma and neutrophilic dermatosis. Arch Dermatol 141:353–356PubMedCrossRef
75.
Nielsen M, Nissen MH, Gerwien J et al (2002) Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated stat 3. Blood 99:973–977PubMedCrossRef
76.
Guenova E, Watanabe R, Teague JE et al (2013) TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 19:3755–3763PubMedPubMedCentralCrossRef
77.
Zhang Q, Nowak I, Vonderheid EC et al (1996) Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 93:9148–9153PubMedPubMedCentralCrossRef
78.
Zhang Q, Raghunath PN, Vonderheid E et al (2000) Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 157:1137–1146PubMedPubMedCentralCrossRef
79.
Qin JZ, Kamarashev J, Zhang CL et al (2001) Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. J Invest Dermatol 117:583–589PubMedCrossRef
80.
Sommer VH, Clemmensen OJ, Nielsen O et al (2004) In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18:1288–1295PubMedCrossRef
81.
Krejsgaard T, Vetter-Kauczok CS, Woetmann A et al (2006) Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 20:1759–1766PubMedCrossRef
82.
Krejsgaard T, Willerslev-Olsen A, Lindahl LM et al (2014) Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood 124:761–770PubMedPubMedCentralCrossRef
83.
Willerslev-Olsen A, Krejsgaard T, Lindahl LM et al (2016) Staphylococcal enterotoxin a (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood 127:1287–1296PubMedPubMedCentralCrossRef
84.
Litvinov IV, Cordeiro B, Fredholm S et al (2014) Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines. Cell Cycle 13:2975–2982PubMedPubMedCentralCrossRef
85.
Nebozhyn M, Loboda A, Kari L et al (2006) Quantitative PCR on 5 genes reliably identifies CTCL patients with 5 % to 99 % circulating tumor cells with 90 % accuracy. Blood 107:3189–3196PubMedPubMedCentralCrossRef
86.
van Doom R, Dijkman R, MH V et al (2004) Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 64:5578–5586CrossRef
87.
88.
Litvinov IV, Pehr K, Sasseville D (2013) Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155. Cell Cycle 12:2172–2173PubMedPubMedCentralCrossRef
89.
Furudate S, Fujimura T, Kakizaki A et al (2016) Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma. J Dermatol Sci 83:182–189PubMedCrossRef
90.
Bao L, Shi VY, Chan LS (2012) IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/stat 6 signal transduction pathway: implication for atopic dermatitis. Mol Immunol 50:91–97PubMedCrossRef
91.
Fujita H, Asahina A, Sugaya M et al (2005) Differential production of Th1- and Th2-type chemokines by mouse Langerhans cells and splenic dendritic cells. J Invest Dermatol 124:343–350PubMedCrossRef
92.
Ohta K, Shigeishi H, Taki M et al (2008) Regulation of CXCL9/10/11 in oral keratinocytes and fibroblasts. J Dent Res 87:1160–1165PubMedCrossRef
93.
Kodelja V, Muller C, Politz O et al (1998) Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 160:1411–1418PubMed
94.
Antonelli A, Ferrari SM, Giuggioli D et al (2014) Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 13:272–280PubMedCrossRef
95.
Zhang Q, Wang HY, Wei F et al (2014) Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. J Immunol 192:2913–2919PubMedPubMedCentralCrossRef
96.
97.
Samimi S, Benoit B, Evans K et al (2010) Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol 146:1382–1388PubMedPubMedCentralCrossRef
98.
Abraham RM, Zhang Q, Odum N et al (2011) The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. Cancer Biol Ther 12:1019–1022PubMedPubMedCentralCrossRef
99.
Wilcox RA, Feldman AL, Wada DA et al (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114:2149–2158PubMedPubMedCentralCrossRef
100.
Kantekure K, Yang Y, Raghunath P et al (2012) Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am J Dermatopathol 34:126–128PubMedPubMedCentralCrossRef
101.
Munir S, Andersen GH, Woetmann A et al (2013) Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells. Leukemia 27:2251–2253PubMedCrossRef
102.
Ni X, Hazarika P, Zhang C et al (2001) Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 7:2682–2692PubMed
103.
Ni X, Zhang C, Talpur R et al (2005) Resistance to activation-induced cell death and bystander cytotoxicity via the fas/fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 124:741–750PubMedCrossRef
104.
Zoi-Toli O, Vermeer MH, De VE et al (2000) Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 143:313–319PubMedCrossRef
105.
Nagasawa T, Takakuwa T, Takayama H et al (2004) Fas gene mutations in mycosis fungoides: analysis of laser capture-microdissected specimens from cutaneous lesions. Oncology 67:130–134PubMedCrossRef
106.
Contassot E, Kerl K, Roques S et al (2008) Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 111:4780–4787PubMedCrossRef
107.
Esmailzadeh S, Huang Y, MW S et al (2015) BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma. Leukemia 29:1402–1413PubMedCrossRef
108.
Kasprzycka M, Zhang Q, Witkiewicz A et al (2008) Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol 181:2506–2512PubMedPubMedCentralCrossRef
109.
Chung JS, Shiue LH, Duvic M et al (2011) Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood 117:3382–3390PubMedPubMedCentralCrossRef
110.
Kadin ME, Cavaille-Coll MW, Gertz R et al (1994) Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci USA 91:6002–6006PubMedPubMedCentralCrossRef
111.
112.
Nakahata S, Yamazaki S, Nakauchi H et al (2010) Downregulation of ZEB1 and overexpression of Smad 7 contribute to resistance to TGF-beta 1-mediated growth suppression in adult T-cell leukemia/lymphoma. Oncogene 29:4157–4169PubMedCrossRef
113.
Brender C, Lovato P, Sommer VH et al (2005) Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 19:209–213PubMedCrossRef
114.
Dobbeling U, Dummer R, Laine E et al (1998) Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 92:252–258PubMed
115.
Marzec M, Halasa K, Kasprzycka M et al (2008) Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 68:1083–1091PubMedCrossRef
116.
Thode C, Woetmann A, Wandall HH et al (2015) Malignant T cells secrete galectins and induce epidermal hyperproliferation and disorganized stratification in a skin model of cutaneous T-cell lymphoma. J Invest Dermatol 135:238–246PubMedCrossRef
117.
Izban KF, Ergin M, Qin JZ et al (2000) Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol 31:1482–1490PubMedCrossRef
118.
Sors A, Jean-Louis F, Pellet C et al (2006) Down-regulating constitutive activation of the NF-kappa B canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107:2354–2363PubMedCrossRef
119.
Kopp KL, Kauczok CS, Lauenborg B et al (2010) COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia 24:1179–1185PubMedCrossRef
120.
Kopp KL, Dabelsteen S, Krejsgaard T et al (2010) COX-2 is a novel target in therapy of mycosis fungoides. Leukemia 24:2127–2129PubMedCrossRef
121.
122.
Rabenhorst A, Schlaak M, Heukamp LC et al (2012) Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood 120:2042–2054PubMedCrossRef
123.
Ionescu MA, Rivet J, Daneshpouy M et al (2005) In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol 52:32–39PubMedCrossRef
124.
Kural YB, Su O, Onsun N et al (2010) Atopy, IgE and eosinophilic cationic protein concentration, specific IgE positivity, eosinophil count in cutaneous T cell lymphoma. Int J Dermatol 49:390–395PubMedCrossRef
125.
Fredholm S, Gjerdrum LM, Willerslev-Olsen A et al (2014) STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Res 34:5277–5286PubMed
126.
Wu X, Schulte BC, Zhou Y et al (2014) Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol 134:2814–2822PubMedCrossRef
127.
Sugaya M, Miyagaki T, Ohmatsu H et al (2012) Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. J Dermatol Sci 68:45–51PubMedCrossRef
128.
Davoine F, Lacy P (2014) Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol 5
129.
130.
Berger CL, Hanlon D, Kanada D et al (2002) The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 99:2929–2939PubMed
131.
Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105:1–8PubMedCrossRef
132.
Vacca A, Moretti S, Ribatti D et al (1997) Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer 33:1685–1692PubMedCrossRef
133.
Lauenborg B, Christensen L, Ralfkiaer U et al (2015) Malignant T cells express lymphotoxin alpha and drive endothelial activation in cutaneous T cell lymphoma. Oncotarget 6:15235–15249PubMedPubMedCentralCrossRef
134.
Pileri A, Agostinelli C, Righi S et al (2015) Vascular endothelial growth factor a (VEGFA) expression in mycosis fungoides. Histopathology 66:173–181PubMedCrossRef
135.
Pedersen IH, Willerslev-Olsen A, Vetter-Kauczok C et al (2013) Vascular endothelial growth factor receptor-3 expression in mycosis fungoides. Leuk Lymphoma 54:819–826PubMedCrossRef
136.
Rook AH, Wood GS, Yoo EK et al (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902–908PubMed
137.
Suchin KR, Junkins-Hopkins JM, Rook AH (2002) Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 138:1137–1139PubMedCrossRef
138.
Dummer R, Hassel JC, Fellenberg F et al (2004) Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104:1631–1638PubMedCrossRef
139.
Wysocka M, Benoit BM, Newton S et al (2004) Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 104:4142–4149PubMedCrossRef
140.
Duvic M, Sherman ML, Wood GS et al (2006) A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 55:807–813PubMedCrossRef
141.
Wysocka M, Newton S, Benoit BM et al (2007) Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma 7:524–534PubMedCrossRef
142.
Kim YH, Girardi M, Duvic M et al (2010) Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 63:975–983PubMedCrossRef
143.
Accart N, Urosevic-Maiwald M, Dummer R et al (2013) Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG 1042. J Transl Med 11:226PubMedPubMedCentralCrossRef
144.
Rook AH, Gelfand JM, Wysocka M et al (2015) Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood 126:1452–1461PubMedPubMedCentralCrossRef
145.
Jackow CM, Cather JC, Hearne V et al (1997) Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood 89:32–40PubMed
146.
Talpur R, Bassett R, Duvic M (2008) Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 159:105–112PubMedCrossRef
147.
Nguyen V, Huggins RH, Lertsburapa T et al (2008) Cutaneous T-cell lymphoma and Staphylococcus aureus colonization. J Am Acad Dermatol 59:949–952PubMedCrossRef
148.
Woetmann A, Lovato P, Eriksen KW et al (2007) Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 109:3325–3332PubMedPubMedCentralCrossRef
149.
Tokura Y, Yagi H, Ohshima A et al (1995) Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigens. Br J Dermatol 133:6–12PubMedCrossRef
150.
Duvic M, Hester JP, Lemak NA (1996) Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 35:573–579PubMedCrossRef
151.
van Doom R, Slieker RC, Boonk SE et al (2016) Epigenomic analysis of Sezary syndrome defines patterns of aberrant DNA methylation and identifies diagnostic markers. J Invest Dermatol 136:1876–1884CrossRef
152.
van Doom R, Zoutman WH, Dijkman R et al (2005) Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p 73. J Clin Oncol 23:3886–3896CrossRef
153.
154.
Cheah MT, Chen JY, Sahoo D et al (2015) CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci USA 112:4725–4730PubMedPubMedCentralCrossRef
155.
Ma X, Aoki T, Tsuruyama T et al (2015) Definition of prostaglandin E2-EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth. Cancer Res 75:2822–2832PubMedCrossRef
156.
Lou Y, Diao L, Cuentas ER et al (2016) Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res 22:3630–3642PubMedCrossRef
157.
Bais AG, Beckmann I, Lindemans J et al (2005) A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 58:1096–1100PubMedPubMedCentralCrossRef
158.
Tosolini M, Kirilovsky A, Mlecnik B et al (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71:1263–1271PubMedCrossRef
159.
Kristensen VN, Vaske CJ, Ursini-Siegel J et al (2012) Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA 109:2802–2807PubMedCrossRef
160.
Gaur P, Singh AK, Shukla NK et al (2014) Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance. Hum Immunol 75:330–337PubMedCrossRef
161.
Datta J, Berk E, Xu S et al (2015) Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res 17
162.
Peng D, Kryczek I, Nagarsheth N et al (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527:249–253PubMedPubMedCentralCrossRef
163.
Si W, Huang W, Zheng Y et al (2015) Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer metastasis. Cancer Cell 27:822–836PubMedCrossRef
164.
De ML, Wormann S, Brunetto E et al (2016) Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients. Cancer Res 76:1792–1803CrossRef
165.
Nagarsheth N, Peng D, Kryczek I et al (2016) PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer. Cancer Res 76:275–282PubMedCrossRef
166.
Subbaramaiah K, Morris PG, Zhou XK et al (2012) Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2:356–365PubMedPubMedCentralCrossRef
Metadata
Title
Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover
Authors
Thorbjørn Krejsgaard
Lise M. Lindahl
Nigel P. Mongan
Mariusz A. Wasik
Ivan V. Litvinov
Lars Iversen
Erik Langhoff
Anders Woetmann
Niels Odum
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 3/2017
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-016-0594-9

Other articles of this Issue 3/2017

Seminars in Immunopathology 3/2017 Go to the issue

Review

Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer

Review

The role of dendritic cells in cancer

Review

T cell receptor repertoire usage in cancer as a surrogate marker for immune responses

Review

Cancer immunotherapy in patients with preexisting autoimmune disorders

Review

Potential importance of B cells in aging and aging-associated neurodegenerative diseases

Introduction

Cancer and autoimmunity

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits